Results 41 to 50 of about 352,135 (348)

LNK (SH2B3): paradoxical effects in ovarian cancer. [PDF]

, 2015
LNK (SH2B3) is an adaptor protein studied extensively in normal and malignant hematopoietic cells. In these cells, it downregulates activated tyrosine kinases at the cell surface resulting in an antiproliferative effect. To date, no studies have examined
Chien, W, Ding, L-W, Doan, NB, Dong, X-M, Garg, M, Gery, S, Hattori, N, Huang, RY-J, Koeffler, HP, Lin, D-C, Liu, L-Z, Meng, X, Said, JW, Sun, Q-Y, Tang, K, Xiao, J-F, Yang, H   +16 more
core   +2 more sources

STAT1 activation in association with JAK2 exon 12 mutations [PDF]

, 2015
La inclusión de la perspectiva de género en la actividad jurisdiccional es una demanda sostenida de los colectivos feministas y de mujeres, dado que las sentencias tienen un poder performativo y envían un mensaje a la sociedad: “[…] tienen un poder ...
Godfrey, A.L., Chen, E., Massie, C.E., Silber, Y., Pagano, F., Bellosillo, B., Guglielmelli, P., Harrison, C.N., Reilly, J.T., Stegelmann, F., Bijou, F., Lippert, E., Boiron, J.M., Dohner, K., Vannucchi, A.M., Besses, C., Green, A.R., Godfrey, A.L., Chen, E., Massie, C.E., Silber, Y., Pagano, F., Bellosillo, B., Guglielmelli, P., Harrison, C.N., Reilly, J.T., Stegelmann, F., Bijou, F., Lippert, E., Boiron, J.M., Dohner, K., Vannucchi, A.M., Besses, C., Green, A.R.   +33 more
core   +4 more sources

The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN

Frontiers in Oncology, 2021
The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis share driver mutations that either activate the thrombopoietin receptor, MPL, or indirectly activate it through mutations in the gene for JAK2, its ...
Jerry L. Spivak, Alison R. Moliterno
doaj   +1 more source

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Leukemia, 2021
We report the clinical presentation and risk factors for survival in 175 patients with myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and June 2020.
T. Barbui, A. Vannucchi, A. Álvarez-Larrán, A. Iurlo, A. Masciulli, A. Carobbio, A. Ghirardi, A. Ferrari, G. Rossi, E. Elli, M. Andrade-Campos, Mercedes Gasior Kabat, J. Kiladjian, F. Palandri, G. Benevolo, V. García‐Gutiérrez, M. Fox, M. Foncillas, C. Morcillo, E. Rumi, S. Osorio, P. Papadopoulos, M. Bonifacio, Keina Susana Quiroz Cervantes, Miguel Sagues Serrano, G. Carreño-Tarragona, M. Sobas, F. Lunghi, A. Patriarca, B. Elorza, A. Angona, Elena Magro Mazo, S. Koschmieder, M. Ruggeri, B. Cuevas, J. Hernández-Boluda, Emma Lopez Abadia, B. X. Cirici, P. Guglielmelli, M. Garrote, D. Cattaneo, R. Daffini, F. Cavalca, B. Bellosillo, L. Benajiba, N. Curto-Garcia, M. Bellini, S. Betti, V. De Stefano, C. Harrison, A. Rambaldi   +50 more
semanticscholar   +1 more source

Myelodysplastic/Myeloproliferative Neoplasms [PDF]

, 2013
AbstractThe myelodysplastic syndrome-myeloproliferative neoplasms (MDS/MPNs) are a heterogeneous group of hematologic malignancies characterized by dysplastic and myeloproliferative clinical, laboratory, and morphological overlapping features, both in marrow and in blood.
Faramarz Naeim, P. Nagesh Rao, Sophie X. Song, Ryan T. Phan   +3 more
openaire   +5 more sources

The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms.

Blood, 2021
Thrombotic, vascular, and bleeding complications are the most common causes of morbidity and mortality in the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs).
H. Hasselbalch, M. Elvers, A. Schafer
semanticscholar   +1 more source

Platelets as mediators of Thromboinflammation in chronic Myeloproliferative Neoplasms [PDF]

, 2019
Chronic myeloproliferative neoplasms (MPN) are stem cell disorders driven by mutations in JAK2, CALR, or MPL genes and characterized by myeloid proliferation and increased blood cell counts.
Heller, Paula Graciela, Marin Oyarzún, Cecilia Paola   +1 more
core   +1 more source

Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera

Blood Cancer Journal, 2022
We investigated the neutrophil-to-lymphocyte ratio (NLR) as a predictor of thrombosis in polycythemia vera (PV). After a median follow-up of 2.51 years, of 1508 PV patients enrolled in the ECLAP study, 82 and 84 developed arterial and venous thrombosis ...
Alessandra Carobbio, Alessandro Maria Vannucchi, Valerio De Stefano, Arianna Masciulli, Paola Guglielmelli, Giuseppe Gaetano Loscocco, Francesco Ramundo, Elena Rossi, Yogendra Kanthi, Ayalew Tefferi, Tiziano Barbui   +10 more
doaj   +1 more source

Practical management of the haemorrhagic complications of myeloproliferative neoplasms

British Journal of Haematology, 2022
Myeloproliferative neoplasms can be associated with bleeding manifestations which can cause significant morbidities. Although haematologists are aware of the likelihood of this complication in the setting of myeloproliferative neoplasms, it may often be ...
E. Jones, Bryan Dillon, D. Swan, J. Thachil   +3 more
semanticscholar   +1 more source

Myelodysplastic/Myeloproliferative Neoplasms

Seminars in Diagnostic Pathology, 2011
The myelodysplastic/myeloproliferative neoplasms (MDS/MPN) include clonal myeloid neoplasms that overlap the MDS and MPN categories and at the time of initial diagnosis exhibit some clinical, laboratory, or morphologic features supporting the diagnosis of myelodysplastic syndrome (MDS) and at the same time show proliferative features in keeping with ...
Elizabeth Hyjek, James W. Vardiman
openaire   +7 more sources